Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer.

Lara, Pedro C; Rodríguez-Melcón, Juan I; Palacios-Eito, Amalia; Lozano, Antonio; Hervás-Morón, Asunción; Villafranca, Elena; Gómez-Iturriaga, Alfonso; Sancho, Gemma; Maldonado, Xavier

Lara, Pedro C; Rodríguez-Melcón, Juan I; Palacios-Eito, Amalia; Lozano, Antonio; Hervás-Morón, Asunción; Villafranca, Elena; Gómez-Iturriaga, Alfonso; Sancho, Gemma; Maldonado, Xavier.

Afiliação

Lara PC; Canarian Comprehensive Cancer Center, San Roque University Hospital, Fernando Pessoa Canarias University, Las Palmas, Spain.
Rodríguez-Melcón JI; Radiation Oncology. Dr. Negrín University Hospital, Las Palmas, Spain.
Palacios-Eito A; Radiation Oncology, Reina Sofía University Hospital, Instituto Maimónides de Investigación Biomédica de Córdoba, Córdoba, Spain.
Lozano A; Radiation Oncology, Virgen de la Arriexaca University Hospital, Murcia, Spain.
Hervás-Morón A; Radiation Oncology, Ramon y Cajal University Hospital, Madrid, Spain.
Villafranca E; Radiation Oncology, Navarra University Hospital, Pamplona, Spain.
Gómez-Iturriaga A; Radiation Oncology, Cruces University Hospital, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
Sancho G; Radiation Oncology, San Creu I San Pau University Hospital, Barcelona, Spain.
Maldonado X; Radiation Oncology, Vall d´Hebron University Hospital, Barcelona, Spain.

Front Oncol ; 12: 891886, 2022.

Article em En | MEDLINE | ID: mdl-35912190

Palavras-chave

enzalutamide monotherapy; hypofractionated; intermediate risk; prostate cancer; radiotherapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google